Dihexa Evidence Guide
Evidence for Dihexa is too preliminary to support a research protocol with confidence. Human data is essentially absent - research is confined to rodent models of cognitive decline. Of the Cognitive & Nootropic compounds, cerebrolysin or semax have at minimum regional human evidence as better-characterized starting points.
Our Take
Evidence for Dihexa is too preliminary to support a research protocol with confidence. Human data is essentially absent - research is confined to rodent models of cognitive decline. Of the Cognitive & Nootropic compounds, cerebrolysin or semax have at minimum regional human evidence as better-characterized starting points.
- Evidence context
- Preclinical cognitive enhancement research, HGF/Met pathway, synaptogenesis models
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No human protocol established - evidence is preclinical only
Benefits and Evidence
- Memory Enhancement: Level D, mostly non-human evidence - McCoy et al. (2013, J Pharmacol Exp Ther) showed Dihexa at picomolar doses (10^-13 M) reversed scopolamine-induced amnesia in rats via Morris water maze and novel object recognition; active at ~10^7-fold lower concentrations than BDNF for HGF/c-Met-dependent synaptogenesis in hippocampal neurons.
- Synaptogenesis: Level D, mostly non-human evidence - In vitro and animal studies demonstrate significant promotion of new synaptic connections. May be relevant for neurodegenerative disease treatment.
Side Effects and Warnings
- No human safety data available
- Theoretical risk of excessive cell growth (HGF pathway)
- Unknown long-term effects
- Quality control concerns with available research material
- EXTREMELY EARLY STAGE - animal data only
- No human clinical trials conducted
- HGF/c-Met pathway involved in cancer cell growth and metastasis
- Serious theoretical safety concerns
Research Dosage References
- <strong>Oral</strong> - 5-20 mg - Once daily - Research dosing extrapolated from animal studies. No established human dosing protocol. Orally bioavailable.
- <strong>Subcutaneous</strong> - 1-5 mg - Once daily - Alternative route used in some research contexts. Higher bioavailability than oral.
Mechanism of Action
Dihexa works through the HGF/c-Met pathway: 1. HGF/c-Met activation: Stabilizes hepatocyte growth factor, enhancing its binding to the c-Met receptor. 2. Synaptogenesis: Promotes formation of new synaptic connections between neurons, enhancing neural network connectivity. 3. Dendritic spine growth: Stimulates growth of dendritic spines, the key structures for synaptic transmission. 4. Neurogenesis: May promote generation of new neurons in hippocampal regions critical for memory. 5. Blood-brain barrier penetration: Small molecular size allows oral bioavailability and CNS penetration.
Legal Status
Dihexa has no regulatory approval for human use. Its identity, purity, and safety outside documented preclinical research settings are not established.
Primary Sources
- Dihexa: a nootropic hexapeptide analog of angiotensin IV. J Pharmacol Exp Ther, 2013.
- The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther, 2014.
Quick Answers
Where is the strongest evidence for Dihexa?
Evidence for Dihexa is too preliminary to support a research protocol with confidence. Human data is essentially absent - research is confined to rodent models of cognitive decline. Of the Cognitive & Nootropic compounds, cerebrolysin or semax have at minimum regional human evidence as better-characterized starting points. Evidence context: Preclinical cognitive enhancement research, HGF/Met pathway, synaptogenesis models.
What are the main side effects of Dihexa?
Dihexa side effects and warning signals include No human safety data available, Theoretical risk of excessive cell growth (HGF pathway), Unknown long-term effects, Quality control concerns with available research material, and EXTREMELY EARLY STAGE - animal data only.
What evidence level is Dihexa?
Dihexa is rated Level D; the listed research status is Preclinical.